A5054628786- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Asthma and respiratory diseases
- Gut microbiota and health
- Microbial infections and disease research
- Helicobacter pylori-related gastroenterology studies
- Clostridium difficile and Clostridium perfringens research
- Tracheal and airway disorders
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Vasculitis and related conditions
- Eosinophilic Disorders and Syndromes
- Acute Ischemic Stroke Management
- Polyomavirus and related diseases
- Drug Transport and Resistance Mechanisms
- Long-Term Effects of COVID-19
- Pharmaceutical studies and practices
- Angiogenesis and VEGF in Cancer
- Virology and Viral Diseases
- Cancer therapeutics and mechanisms
- Congenital Diaphragmatic Hernia Studies
- Rabies epidemiology and control
- Cardiac tumors and thrombi
- Cancer Research and Treatments
- Brain Metastases and Treatment
Kumamoto University Hospital
2017-2024
Kumamoto University
2021-2024
Akita University
2021
Kumamoto City Hospital
2020
Oral microbiota is associated with human diseases including cancer. Emerging evidence suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into gut, negatively influence efficacy of immune checkpoint blockade (ICB) in cancer patients. However, currently there no effective treatment restores decreased efficacy. To address this issue, we retrospectively evaluated 118 advanced or recurrent non-small cell lung (NSCLC) patients treated ICB and analyzed 80...
The gut microbiota has emerged as a key regulator of immune checkpoint inhibitor (ICI) efficacy. Therapeutic approaches aimed at manipulating the through targeted reconstitution to enhance cancer treatment outcomes have garnered considerable attention. A single live microbial biotherapeutic bacterium, Clostridium butyricum MIYAIRI 588 strain (CBM588), been shown effects ICI monotherapy in patients with advanced lung cancer. However, whether CBM588 affects chemoimmunotherapy combinations...
Abstract A 29‐year‐old man presented to our hospital with severe eosinophilic asthma. He needed a short OCS burst for exacerbation of asthma once every 1 or 2 months, although he used high dose inhaled corticosteroids and long‐acting beta‐2 agonists. Chest CT showed multiple mucous plugs bronchiectasis, but further examination found that did not meet the diagnostic criteria allergic bronchopulmonary aspergillosis. After starting dupilumab his asthma, control improved without exacerbation....
Sebaceous carcinoma is a rare cutaneous malignant tumor, usually occurring on the eyelids, head, neck, and trunk. There have been few reports about sebaceous with primary lung cancer, for which optimal therapy has not yet established. A 70-year-old man presented mass in left iliac bone tumor of lower lung. The morphological characteristics biopsy pathology immunostaining results showed gland differentiation. After systemic examination, we diagnosed intrapulmonary metastases. PD-L1 was...
症例は42歳男性．10歳時に近医で骨髄性プロトポルフィリン症（Erythropoietic protoporphyria：EPP）と診断され，20歳，40歳時にEPPによる肝障害，腹痛で入院歴あり，安静で改善した．2014年6月に腹痛，便秘，黄疸が出現し，EPP急性発作の診断で入院となった．遮光下で安静，緩下剤の投与を行うも改善せず，T-Bilの上昇（17.1 mg/dL）を認めた．入院5日目からHeminの投与を行い，投与終了後より徐々にT-Bilは低下，腹痛は改善傾向となった．以降は増悪なく入院30日目に退院となり，退院2カ月後の採血では肝機能，T-Bilは正常化していた．肝障害を伴う急性発作が出現し，治療に難渋したEPPの1例を経験したので報告する．
Background: The clinical impact of tumor microvessels on the efficacy epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in EGFR mutation-positive non-small cell lung cancer (NSCLC) is unclear. Thus, aim this study was to investigate whether a microenvironment, abundant microvessels, affects EGFR-TKI patients with NSCLC and mutations. Methods: We retrospectively studied data 40 post-operative recurrent mutations who received EGFR-TKIs as first-line treatment at Kumamoto...
Pulmonary tumor embolisms (PTEs) are primarily caused by adenocarcinoma. However, only a few cases of oropharyngeal carcinoma have been reported. We herein report 47-year-old man who presented with fever, cough, and dyspnea 6 months after treatment for stage II carcinoma. Chest computed tomography revealed centrilobular granular nodular shadows subpleural consolidation. A transbronchial lung biopsy mass squamous cells forming emboli in the small vessels, resulting diagnosis PTE due to...
Abstract Purpose Microvessel density plays an essential role in tumor development. However, whether a microenvironment, abundant microvessels, affects epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) efficacy patients with non-small cell lung cancer (NSCLC) and EGFR mutations remains unclear. We aimed to investigate the impact of microvessels on EGFR-TKI NSCLC mutations. Methods retrospectively studied data 40 post-operative recurrent who received EGFR-TKIs as first-line...
Abstract The aim of this study was to investigate whether a tumor microenvironment, abundant in microvessels, affects epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) efficacy patients with non-small cell lung cancer (NSCLC) and EGFR mutations. We retrospectively studied the data 40 post-operative recurrent NSCLC mutations who received EGFR-TKIs as first-line treatment at Kumamoto University Hospital between January 2010 February 2021. Tumor sections were retrieved from...
Background and Aims: We found that a lower concentration of plasma gefitinib was associated with shorter progressionfree survival in patients non-small cell lung cancer (NSCLC).Previous reports have shown proton-pump inhibitors (PPIs) inhibit not only absorption but also the ability transporter, ATP-binding castle protein G2 (ABCG2).It is considered to negatively control activity certain transporters, maintaining concentration.The C421A polymorphism affects membrane level ABCG2.We measured...
Background and Aims: We found that a lower concentration of plasma gefitinib was associated with shorter progressionfree survival in patients non-small cell lung cancer (NSCLC).Previous reports have shown proton-pump inhibitors (PPIs) inhibit not only absorption but also the ability transporter, ATP-binding castle protein G2 (ABCG2).It is considered to negatively control activity certain transporters, maintaining concentration.The C421A polymorphism affects membrane level ABCG2.We measured...